Cannabis-based Sublingual Tablet to Enter Trials in Israel as Possible Spasticity Treatment, OWCP Says

Cannabis-based Sublingual Tablet to Enter Trials in Israel as Possible Spasticity Treatment, OWCP Says

OWC Pharmaceutical Research is planning new clinical studies to evaluate the activity and safety of its cannabinoid-enriched sublingual soluble tablet. The company announced that an Institutional Review Board (IRB) in Israel approved its request to conduct a safety and tolerability trial there.

The company also is asking to amend the study design, allowing the trial to compare its tablet formulation with the known cannabis-based therapy Sativex (nabiximols, by GW Pharmaceuticals), a nasal spray that is approved in Europe and elsewhere to treat spasticity in patients with multiple sclerosis (MS). Sativex is not approved by the U.S. Food and Drug Administration (FDA) for use in that country.

The Israel Medical Cannabis Agency (IMCA) also gave OWCP permission to conduct a study looking at the efficacy of the cannabinoid-enriched sublingual disintegrating tablet in treating chronic pain syndrome.

These studies are planned to take place at the Sourasky Academic Medical Center in Tel Aviv, and are expected to start in early 2019.

“OWCP’s sublingual disintegrating tablet will offer an alternative to smoking and inhalation, allowing for controlled, consistent dosing and diligent compliance to medical regimens and offer quick pain and other symptoms relief as sublingual absorption provides a direct route for cannabis to enter much quicker to the blood system,” Mordechai Bignitz, the company’s CEO, said in a press release.

Increasing evidence suggests that cannabis and cannabinoid-based products can help patients manage the symptoms of various diseases, including MS. Studies have demonstrated that such medicines can reduce pain, uncontrolled contraction of muscles, and muscle stiffness (spasticity).

As a result of its therapeutic benefits, cannabinoid-based products are increasingly available and requested by patients. It is estimated that about 16 percent of MS patients use cannabis for medicinal purposes.

Medical cannabis is most commonly administered are through smoking and inhalation. But OWCP in its release and other researchers note that these methods can lack precision in terms of the amount or concentration of active cannabinoids in the therapy. Smoking is also linked to potentially damaging side effects, and is increasingly viewed  negatively in social situations.

OWCP said it developed the cannabinoid-enriched sublingual soluble tablets to provide an effective alternative to smoking.


  1. Edith Cheney says:

    80 years old, 40 years of MS, always use walker but can only walk very short distance, scooter for distance. SPMS for 20 years. Pain is not well controlled by Ibuprofen and spasticity and stiffness are poorly controlled by Klonipin since I can’t take Baclofen. Thank you Israel for all the people you will help have a better quality of life. It is too late for me and others in USA. How can we be so unenlightened while so many suffer?

    • Cognitive Dissonance says:

      Did you ever vote for GOP candidates? They fight tooth and nail to strip people of medicine that doesn’t cost $1000 per month. US is 50 years behind monkeys in seeing that Cannabis cures, so that is your answer.

    • Howie says:

      It’s not available in the US because your country and government has cannabis still scheduled as a harmful drug just like heroin and cocaine…

  2. Diane says:

    Good luck with the trials! Very interested in watching the trial results and wish I could participate. Thank you to everyone who is getting this in motion. God Bless!

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This